Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

July 18, 2024

https://www.globenewswire.com/news-release/2024/07/18/2915261/0/en/Microbot-Medical-Completes-the-Enrollment-of-Clinical-Sites-in-Its-Pivotal-Human-Clinical-Trial-with-the-Addition-of-Memorial-Sloan-Kettering-Cancer-Center.html

BRAINTREE, Mass., July 18, 2024 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq:MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces it has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Center, located in New York City, New York. Memorial Sloan Kettering Cancer Center will conduct the clinical trial as part of the Investigational Device Exemption (“IDE”) for LIBERTY®, and the Company expects its results will support the future marketing submission to the FDA and subsequent commercialization.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.